Efficacy of Gastroretentive Gabapentin for PHN in Real-World Clinical Practice
the MPR take:
How does gastroretentive gabapentin for the treatment of postherpetic neuralgia (PHN) fare in real-world clinical practice? A new study published in the Clinical Journal of Pain aimed to find out. The study population included 190 patients, 110 being ≤70 years of age and 80 being >70 years old. Patients were titrated to 1800mg of gastroretentive gabapentin per day (2 week titration period followed by 6 weeks of treatment at that dose). Efficacy was assessed using the Brief Pain Inventory (BPI) and the visual analog scale (VAS). At the end of the 8-week study patients were also asked to report how they felt using the Patient/Clinician Global Impression of Change (PGIC/CGIC) scales. Results of the study included the following:
- Mean % change in VAS score: -21.3% (≤70yrs), -20.4% (>70yrs)
- % of patients with ≥30% reduction in VAS: 51.8% (≤70yrs), 55.0% (>70yrs)
- % of patients with ≥50% reduction in VAS: 42.7% (≤70yrs), 37.5% (>70yrs)
- BPI scores significantly reduced
- % of patients reported feeling “much” or “very much” improved: 59.0% (≤70yrs), 40.3% (>70yrs)
Most common ADR was dizziness and somnolence Based on the study results, gastroretentive gabapentin appears to be a well-tolerated and effective option for PHN patients.
Objectives: To evaluate the safety and effectiveness of once-daily gastroretentive gabapentin (G-GR) for treatment of PHN in real-world clinical practice. Methods: Patients aged ≥18 years were divided into 2 cohorts: patients ≤70 years and patients >70 years.